Quite a few ongoing clinical studies are concentrating on prostate cancer (NCT03338790, NCT04926181) and hormone receptor-positive/HER2-negative (HR+/HER2−) advanced breast cancer (NCT03393845). Here, ERBB2 is linked to breast cancer.